Airbus Cuts Jet Production Target Amid Pratt & Whitney Engine Shortages, Q4 Profit Jumps 17% 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Federal Court Fines Mobil Oil Australia A$16 Million for Misleading Fuel Claims 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Yotta to Build $2 Billion AI Data Centre Hub in India with Nvidia Blackwell Ultra Chips 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
Medical Groups Sue FTC Over Gender-Affirming Care Investigations Amid Trump Policy Dispute 
India AI Impact Summit 2026: Global Tech CEOs Join World Leaders in New Delhi 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Vietnam Airlines, Vietjet, and Sun PhuQuoc Airways Sign Major Boeing Aircraft Deals Amid U.S.–Vietnam Trade Talks 
Microsoft Responds to ICE Surveillance Concerns Amid Azure Cloud Expansion 
Heidelberg, Germany, May 3, 2018 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at Deutsche Bank's 43rd Annual Health Care Conference on Tuesday, May 8, 2018 at 10:40 am ET.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected], I[email protected]
